Osang Healthcare Co.,Ltd researches, develops, and sells various diagnostic biosensors in South Korea and internationally. The company offers diagnostic biosensors for blood glucose, hemoglobin A1c, cholesterol, immuno diagnosis, molecular diagnosis, and others. It also exports its products to approximately 110 countries worldwide. The company was formerly known as Infopia Co., Ltd. and changed its name to Osang Healthcare Co.,Ltd in April 2017. Osang Healthcare Co.,Ltd was founded in 1996 and is headquartered in Anyang, South Korea.

Osang Healthcare Co.,Ltd

Founded in 1996, OSANG Healthcare is a leader in the In-Vitro Diagnostics (IVD) market and is one of the fastest-growing medical device manufacturing and distribution company in the nation, employing over 315 industry experts (52 in Research & Development/27 + PhD/MSc)

We are at the forefront of manufacturing premium diagnostic devices, specializing in blood glucose, HbA1c, cholesterol, PCR testing solutions to over 110 countries worldwide. 

Our commitment to excellence was demonstrated during the pandemic when we became a pivotal supplier of COVID-19 test kits globally, showcasing our agility and dedication to public health. In 2023, we distributed 100 million COVID-19 Antigen Tests nationwide through Federal Agencies, and the only company in the world to be selected by National Institutes of Health(NIH) Independent Test Assessment Program(ITAP) twice for both OHC COVID-19 Antigen Test and COVID-19/Flu Antigen Test.

Our goal is to be the premier researcher and developer of diagnostic sensors for a comprehensive range of diseases, ensuring a healthier future for all.

Contact Us:
sales@osangllc.com

OSANG LLC

🚀 OSANG Healthcare invests in CGM Technology 🚀

We are thrilled to announce our recent strategic investment in Allez Health, an innovative developer of Continuous Glucose Monitoring (CGM) systems. 

Since its inception in 2018, Allez Health (Formerly Zense Life) has been at the forefront of diabetes management technology. This partnership, involving an investment of approximately $36 million, marks an important step as Allez Health prepares for rigorous FDA approval processes in the US, Europe, and Asia. 

Our commitment to advancing healthcare technology together promises to enhance competitive edges in the global CGM market. Stay tuned for more updates on this groundbreaking journey! 

#HealthcareInnovation #CGM #OSANG #Allez #Zense #Diabetics #Glucose #OHC #OKRA #PublicHealth

Cases of children experiencing mental health issues have been on the rise following the long pandemic.

Dr. Erica Locke of Salinas Valley Health highlights a troubling trend in children's mental health, noting a significant rise in emergency psychiatric hospitalizations over the past few years, possibly exacerbated by pandemic-induced isolation. 

A study by the Children's Hospital of Chicago confirms this trend, particularly among girls. Locke emphasizes the urgent need for long-term investment in mental health infrastructure for children.

#ChildrensMentalHealth #PublicHealth #OSANG #OHC #COVID 💡

🌟 OSANG Healthcare has achieved a major milestone by obtaining certification for the European In Vitro Diagnostic Medical Devices Regulation (IVDR) for personal blood glucose meters! 

This certification, awarded by the prestigious certification body BSI, underscores OSANG Healthcare's commitment to excellence in product performance and safety. With this achievement, OSANG Healthcare strengthens its foothold in the European market and paves the way for expanded global market share. 

#HealthcareInnovation #IVDR #OsangHealthcare #OHC #EU #CE #BloodGlucose #PublicHealth


🔍Understanding Type 2 Diabetes: Causes, Signs, and Prevention🩺

Type 2 diabetes presents a significant health challenge, yet with proper management, its impact can be mitigated. 

Vigilance is crucial, with symptoms such as persistent thirst, increased urination, fatigue, unexplained weight loss, vision problems, and tingling sensations indicating possible onset.

Begin your health journey with the OKRA Pro Starter Kit, equipped with bluetooth-enabled glucose meter, test strips with a dedicated mobile app, and prioritize preventive health measures today.

#DiabetesAwareness #PreventiveHealth #OKRAPro #OHC #OSANGLLC #OKRA #BloodGlucose #PublicHealth #Diabetes🌿👩‍⚕️

📈 OSANG Healthcare, a leading South Korean IVD Manufacturer, has made a strategic decision to invest $10M in Kryptos Biotechnologies' Series A funding round. 

Based in Hayward, California, Kryptos Biotechnologies is revolutionizing molecular diagnostics with its innovative Kuick platform, utilizing photothermal heating and Ultrafast Photonic PCR to deliver rapid results in just 20 minutes. 

With this significant investment, Kryptos Biotechnologies aims to accelerate clinical studies for its respiratory combination tests, targeting FDA approval by 2025. Additionally, this partnership will facilitate manufacturing and distribution of Kryptos Biotechnologies' groundbreaking products. 

Stay tuned for more updates as we continue to lead the way in point-of-care testing innovation! 🌟💼

#Kryptos #Partnership #Innovation #OSANG #OHC #COVID19 #Investment #POC #Laboratory #Clinical

👨‍🔬 Are you a diabetic, but NOT overweight?

The study created a rat model of type 2 diabetes without overweight or overeating by feeding them soft processed foods (SPs) on a restricted schedule for 24 weeks. 

These rats exhibited characteristics of type 2 diabetes such as glucose intolerance, insulin resistance, and fat accumulation despite having normal weight. 

Muscle atrophy was observed in these rats, which was linked to reduced insulin signaling in muscle cells and activation of the ubiquitin-proteasome pathway mediated by elevated levels of interleukin-6 (IL-6).  The study suggests that the consumption of processed foods may contribute to the development of type 2 diabetes and associated muscle atrophy through mechanisms involving IL-6 signaling.

Follow for more public health insights! 

#OSANG #OHC #DiabetesManagement #OKRA #PublicHealth

	Dec '21	Dec '22	Dec '23
net income	1.46B -	40.65B 2,683.22%	116.44B 186.46%
depreciation and amortization	3.96B -	5.41B 36.75%	6.32B 16.87%
deferred income tax
stock based compensation	3.09B -	2.70B 12.85%	1.86B 31.02%
change in working capital	7.12B -	-27.79B 490.09%	12.19B 143.85%
accounts receivables	1.75B -	-20.00B 1,239.62%	19.59B 197.95%
inventory	4.19B -	-26.95B 742.68%	20.10B 174.60%
accounts payables	-1.01B -	12.09B 1,291.19%	-14.58B 220.61%
other working capital	2.19B -	7.06B 222.07%	-12.92B 282.98%
other non cash items	1.25B -	69.76B 5,497.83%	5.19B 92.56%
net cash provided by operating activities	10.81B -	42.35B 291.90%	152.60B 260.29%
investments in property plant and equipment	-9.90B -	-11.90B 20.23%	-35.88B 201.50%
acquisitions net	87.98M -	715.05M 712.74%	14.61B 1,942.82%
purchases of investments	-5.34B -	-31.51B 490.17%	-109.02B 245.98%
sales maturities of investments	9.06B -	15.20B 67.77%	74.77B 391.87%
other investing activites	10.00M -	-15.79B 158,032.36%	10 100.00%
net cash used for investing activites	-6.08B -	-27.50B 352.31%	-55.53B 101.95%
debt repayment	-2B -	-625.08M 68.75%	-592.47M 5.22%
common stock issued	288M -	2.57B 792.50%	714.38M 72.21%
common stock repurchased
dividends paid	-24.53B -	-24.90B 1.47%	-25.35B 1.82%
other financing activites	6.61M -	2.57B 38,791.46%	714.38M 72.21%
net cash used provided by financing activities	-26.54B -	-22.95B 13.53%	-25.23B 9.92%
effect of forex changes on cash	18.02M -	-874.74M 4,953.86%	-366.29M 58.13%
net change in cash	-21.79B -	-8.97B 58.86%	71.48B 897.15%
cash at beginning of period	68.90B -	47.11B 31.63%	38.14B 19.03%
cash at end of period	47.11B -	38.14B 19.03%	109.62B 187.40%
operating cash flow	10.81B -	42.35B 291.90%	152.60B 260.29%
capital expenditure	-9.90B -	-11.90B 20.23%	-35.88B 201.50%
free cash flow	908.90M -	30.45B 3,250.47%	116.71B 283.26%

0362

COM:OSANGHC

OsanGHC

Last Close

11,400.00

22/11 06:30

Market Cap

223.26B

Beta: -

Volume Today

9.28K

Avg: -

Preview